BioAdvance News

Merganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides

By WebmasterFebruary 19, 2015November 1st, 2024No Comments

Merganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides
Read more here

Previous PostMelior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes
Next PostRelmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone